Genetics of osteoporosis: perspectives for personalized medicine. (November 2010)

• Record Type: Journal Article
• Authors: Li, Wen-Feng; Hou, Shu-Xun; Yu, Bin; Jin, Dan; Férec, Claude; Chen, Jian-Min
• Is Part Of: Personalized medicine. Volume 7:Number 6(Year 2010)
• Page Start: 655
• Page End: 668
• Publication Date: 2010-11
• Subjects: BMD -- bone formation -- bone resorption -- estrogen-replacement therapy -- osteoblasts -- osteoclasts -- osteoporosis susceptibility gene -- osteoporotic fracture -- rare variants -- sclerostin antibody -- serotonin -- SNP; Pharmacogenomics -- Periodicals; Pharmacogenetics -- Periodicals; 615.19
• DOI: 10.2217/pme.10.55
• Languages: English
• ISSNs: 1741-0541

Abstract

Osteoporosis is the most common metabolic bone disorder worldwide. At least 15 genes (e.g., ESR1, LRP5, SOST, OPG, RANK and RANKL ) have been confirmed as osteoporosis susceptibility genes, and another 30 have been highlighted as promising susceptibility genes. Notably, these genes are clustered in three biological pathways: the estrogen endocrine pathway, the Wnt/β-catenin signaling pathway and the RANK/RANKL/osteoprotegerin (OPG) pathway. In this article, using data pertaining to these three biological pathways as examples, we illustrate possible principles of personalized therapy for osteoporosis. In particular, we propose to use inhibitors (e.g., denosumab) of the RANK/RANKL/OPG signaling pathway to circumvent resistance to estrogen-replacement therapy: a novel idea resulting from the consideration of a mechanistic link between the estrogen endocrine pathway and the RANK/RANKL/OPG signaling pathway. In addition, we call for more attention to be focused on rare variants of major effects in future studies.